TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-kappa B and Regresses Mutant EGFR-Associated Human Non-Small Cell Lung Cancers

CORC > 兰州大学 > 兰州大学 > 生命科学学院 > 期刊论文

	TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-kappa B and Regresses Mutant EGFR-Associated Human Non-Small Cell Lung Cancers
	Nan, J; Du, YP; Chen, X; Bai, QF; Wang, YX; Zhang, XX; Zhu, N; Zhang, J; Hou, JW; Wang, Q
刊名	MOLECULAR CANCER THERAPEUTICS
	2014-03
卷号	13 期号:3 页码:617-629
ISSN号	1535-7163
通讯作者	Yang, JB (reprint author), Lanzhou Univ, Sch Life Sci, Lanzhou 730000, Gansu, Peoples R China.
学科主题	Oncology
语种	英语
WOS记录号	WOS:000334318300007
内容类型	期刊论文
源URL	[http://ir.lzu.edu.cn/handle/262010/115437]
专题	生命科学学院_期刊论文
推荐引用方式 GB/T 7714	Nan, J,Du, YP,Chen, X,et al. TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-kappa B and Regresses Mutant EGFR-Associated Human Non-Small Cell Lung Cancers[J]. MOLECULAR CANCER THERAPEUTICS,2014,13(3):617-629.
APA	Nan, J.,Du, YP.,Chen, X.,Bai, QF.,Wang, YX.,...&Yang, JB.(2014).TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-kappa B and Regresses Mutant EGFR-Associated Human Non-Small Cell Lung Cancers.MOLECULAR CANCER THERAPEUTICS,13(3),617-629.
MLA	Nan, J,et al."TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-kappa B and Regresses Mutant EGFR-Associated Human Non-Small Cell Lung Cancers".MOLECULAR CANCER THERAPEUTICS 13.3(2014):617-629.